Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Robinson, Stephen [VerfasserIn]   i
 Boumendil, A. [VerfasserIn]   i
 Finel, H. [VerfasserIn]   i
 Blaise, D. [VerfasserIn]   i
 Poiré, X. [VerfasserIn]   i
 Nicolas-Virelizier, E. [VerfasserIn]   i
 Or, R. [VerfasserIn]   i
 Malladi, R. [VerfasserIn]   i
 Corby, A. [VerfasserIn]   i
 Fornecker, L. [VerfasserIn]   i
 Caballero, D. [VerfasserIn]   i
 Pohlreich, D. [VerfasserIn]   i
 Nagler, A. [VerfasserIn]   i
 Thieblemont, C. [VerfasserIn]   i
 Finke, J. [VerfasserIn]   i
 Bachy, E. [VerfasserIn]   i
 Vincent, L. [VerfasserIn]   i
 Schroyens, W. [VerfasserIn]   i
 Schouten, H. [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
Titel:Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma
Titelzusatz:efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
Verf.angabe:S.P. Robinson, A. Boumendil, H. Finel, D. Blaise, X. Poiré, E. Nicolas-Virelizier, R. Or, R. Malladi, A. Corby, L. Fornecker, D. Caballero, D. Pohlreich, A. Nagler, C. Thieblemont, J. Finke, E. Bachy, L. Vincent, W. Schroyens, H. Schouten and P. Dreger
Jahr:2016
Jahr des Originals:2015
Umfang:7 S.
Fussnoten:Published online 30 November 2015 ; Gesehen am 30.04.2020
Titel Quelle:Enthalten in: Bone marrow transplantation
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2016
Band/Heft Quelle:51(2016), 3, Seite 365-371
ISSN Quelle:1476-5365
Abstract:In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.
DOI:doi:10.1038/bmt.2015.286
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1038/bmt.2015.286
 Volltext: https://www.nature.com/articles/bmt2015286
 DOI: https://doi.org/10.1038/bmt.2015.286
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1696971314
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68572292   QR-Code
zum Seitenanfang